» Articles » PMID: 38067415

Simultaneous Measurement and Distribution Analysis of Urinary Nicotine, Cotinine, Trans-3'-Hydroxycotinine, Nornicotine, Anabasine, and Total Nicotine Equivalents in a Large Korean Population

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Dec 9
PMID 38067415
Authors
Affiliations
Soon will be listed here.
Abstract

Measurement of multiple nicotine metabolites and total nicotine equivalents (TNE) might be a more reliable strategy for tobacco exposure verification than measuring single urinary cotinine alone. We simultaneously measured nicotine, cotinine, 3-OH cotinine, nornicotine, and anabasine using 19,874 urine samples collected from the Korean National Health and Nutrition Examination Survey. Of all samples, 18.6% were positive for cotinine, 17.4% for nicotine, 17.3% for nornicotine, 17.6% for 3-OH cotinine, and 13.2% for anabasine. Of the cotinine negative samples, less than 0.3% were positive for all nicotine metabolites, but not for anabasine (5.7%). The agreement of the classification of smoking status by cotinine combined with nicotine metabolites was 0.982-0.994 (Cohen's kappa). TNE3 (the molar sum of urinary nicotine, cotinine, and 3-OH cotinine) was most strongly correlated with cotinine compared to the other nicotine metabolites; however, anabasine was less strongly correlated with other biomarkers. Among anabasine-positive samples, 30% were negative for nicotine or its metabolites, and 25% were undetectable. Our study shows that the single measurement of urinary cotinine is simple and has a comparable classification of smoking status to differentiate between current smokers and non-smokers relative to the measurement of multiple nicotine metabolites. However, measurement of multiple nicotine metabolites and TNE3 could be useful for monitoring exposure to low-level or secondhand smoke exposure and for determining individual differences in nicotine metabolism. Geometric or cultural factors should be considered for the differentiation of tobacco use from patients with nicotine replacement therapy by anabasine.

Citing Articles

Determination of Cotinine, 3'-Hydroxycotinine and Nicotine 1'-Oxide in Urine of Passive and Active Young Smokers by LC-Orbitrap-MS/MS Technique.

Szumska M, Mroczek P, Tyrpien-Golder K, Pastuszka B, Janoszka B Molecules. 2024; 29(15).

PMID: 39125048 PMC: 11313786. DOI: 10.3390/molecules29153643.

References
1.
Al-Delaimy W, Willett W . Measurement of tobacco smoke exposure: comparison of toenail nicotine biomarkers and self-reports. Cancer Epidemiol Biomarkers Prev. 2008; 17(5):1255-61. DOI: 10.1158/1055-9965.EPI-07-2695. View

2.
Zhu A, Renner C, Hatsukami D, Swan G, Lerman C, Benowitz N . The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):708-18. PMC: 3617060. DOI: 10.1158/1055-9965.EPI-12-1234-T. View

3.
Benowitz N, St Helen G, Dempsey D, Jacob 3rd P, Tyndale R . Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. Pharmacogenet Genomics. 2016; 26(7):340-50. PMC: 4892970. DOI: 10.1097/FPC.0000000000000222. View

4.
Kawasaki Y, Li Y, Watanabe S, Ootsuyama Y, Kawai K . Urinary biomarkers for secondhand smoke and heated tobacco products exposure. J Clin Biochem Nutr. 2021; 69(1):37-43. PMC: 8325761. DOI: 10.3164/jcbn.20-183. View

5.
Suh-Lailam B, Haglock-Adler C, Carlisle H, Ohman T, McMillin G . Reference interval determination for anabasine: a biomarker of active tobacco use. J Anal Toxicol. 2014; 38(7):416-20. DOI: 10.1093/jat/bku059. View